Overview
Objectives
- Discover therapeutic advances in standardized transplants, cell-based products, blood products, complex and personalized medicines and innovative drug combinations
- Acquire specialized knowledge of the different innovative therapies and their interaction with biological tissues
- Understand the good manufacturing practices (GMP) required for these new types of medicines
- Develop skills in quality control, quality assurance, and regulatory affairs
- Understand the determinants of clinical applications of ATMPs and combinatorial therapies
Audience
Healthcare professionals and scientists interested in the emerging field of advanced therapies, including pharmacists, physicians, medical researchers, biologists, healthcare engineers, biostatisticians.
Programme
7 modules :
- Cellular therapy – from bench to bedside
- Immunology
- Transfusion medicine – science and technology from donor to patient
- Combinatorial strategies in cancer treatment
- Oncology: innovative therapies
- Phage therapy
- Nanomedicines
Diploma awarded
The Certificate of Advanced Studies (CAS) in Advanced Therapy Medicinal Products delivered by the universities of Lausanne and Geneva.
Registration
Registration deadline
Contact coordinator
Fees:
CHF 6'000.-
Admission criteria
- Hold a bachelor’s or master’s degree from a Swiss or foreign university (HEU), from a University of Applied Sciences (HES), or hold another title deemed equivalent by the Steering Committee, and
- Have a minimum of 1 year of professional experience in the health care field
Application File
Admission on file to submit to Formation Continue UNIL-EPFL. Please join to the registration form:
- Letter of motivation
- CV
- Copies of diplomas obtained
Curriculum
Period
Contact coordinator
Credits
16 ECTS credits
Teaching hours
38 teaching hours
84 distance teaching hours
Advanced therapy medicinal products (ATMPs) such as cell therapy, tissue-engineered medicine or immunotherapy, as well as innovative medicines like phage therapy or nanomedicine, are pushing the boundaries of currently available treatments. Oncology, reconstructive surgery, orthopaedic surgery, neurosurgery, blood transfusion, infectious diseases – clinical applications are numerous.
Providing healthcare professionals with a thorough understanding of these therapeutic breakthroughs is essential to ensure the effective transition of these innovative treatments and care techniques from the bench to the bedside.
Providing healthcare professionals with a thorough understanding of these therapeutic breakthroughs is essential to ensure the effective transition of these innovative treatments and care techniques from the bench to the bedside.
Description
- Principles of translational science
Cell biology / Preclinical relevance and evaluation / Biological products specificities - Types of cellular therapy
Sources of cells / Clinical targets / Clinical strategies / Histocompatibility - Clinical trials of cellular therapy
Examples of human applications: burn patients, orthopedics, neuroscience - Regulatory aspects of cellular therapy
Basis in EU and Switzerland for Good Manufacturing Practices (GMP), Good Clinical Practices (GCP) & ATMPs specificities - Production of cellular therapy
GMP / Clean room / Manufacturing technologies / T cells - Visit of a GMP cellular manufacturing facility
Speakers
Prof. Lana KANDALAFT and Dr. Jean-François BRUNET
Description
- Introduction to immunology
Organs, tissues, functions of the immune system / Innate & adaptive immunity - Analytical immunology
Overview / Biomarkers / Immune correlates - Limitations of immunotherapies
Tolerance and autoimmunity / Toxicity /Side effects
Speakers
Prof. Alexandre HARARI
Description
- Introduction to transfusion medicine
Historical developments / Transfusion chain / Blood groups / Immunohematology / Transfusion-related risks - Biology and biochemistry of blood products
Red blood cells and platelets / Fresh frozen Plasma - Medical aspects
Needs and use of blood products / Apheresis / Hematopoietic stem cells / Clinical cases and practices - Production and regulatory aspects
Blood & special products preparation and manufacturing / Regulations and GMP - Visits of production site and diagnostic labs
Speakers
Prof. Michel PRUDENT
Description
- Combination therapy
Advantages vs. monotherapy / Combinations strategies in various cancer types / Anti-angiogenic immunotherapy / Pharmacokinetics and pharmacodynamics / Drug resistance principles / Cell death in cancer therapy - Preclinical development
Drug repurposing / Drug interactions and synergies / Immunotargeting / Cell mitosis - Clinical development
Clinical trial development / Successful clinical trials examples / New combination strategies for cancer treatment design - Visit of research laboratories of cell biology and pharmacology
Speakers
Prof. Patrycja NOWAK-SLIWINSKA
Description
- Immunotherapy
Cellular and drug immunotherapies / Checkpoint inhibitors / Monoclonal antibodies - Personalized cellular immunotherapy
Chimeric Antigen Receptor (CAR) T cell / Vaccines / HSCT / Personalized medicine
Speakers
Dr. Francesco CEPPI
Description
- Introduction to phage therapy
Antibiotic resistance / Bacteriophages / History of phage discovery & phage therapy - Phage banks and production
Personalized phage therapy / Phages production processes - Phage-based pharmaceutical products regulations
Regulation challenges / GMP Basics - Modern translational studies and clinical studies
Phage-antibiotic synergism / Human applications - Practical course
Bacteriophage isolation from the environment
Speakers
Dr. Grégory RESCH
Description
- Introduction to nanomedicines
Nanomedicines types / Nanotechnology applications to drug therapies and vaccines / Pharmacokinetics & pharmacodynamics - Nanomedicines technology
Physiochemical properties biocompatibility / Nanoformulations / Critical Quality Attributes (CQAs) - Production and regulatory aspects
FDA and EMA regulations / The many challenges of nanomedicines development, production and clinical practices
Speakers
Prof. Gerrit BORCHARD
Partnerships / Collaboration
Diploma delivered jointly by
University of Geneva, University of Lausanne
Director(s)
Prof. Chantal CSAJKA, Faculty of Science, University of Geneva and Prof. Lana KANDALAFT, Faculty of Biology and Medicine, University of Lausanne
Coordinator(s)
Marion CHASSOT, Lausanne University Hospital (CHUV)
Steering committee
- Prof. Chantal CSAJKA, Full professor, Director of the Centre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and UNIL; School of Pharmaceutical Sciences, UNIGE
- Prof. Lana KANDALAFT, Chief of Service – Center of Experimental Therapeutics, Lausanne University Hospital and UNIL ; Associate Director for Clinical Translation – Ludwig Institute for Cancer Research
- Prof. Patrycja NOWAK-SLIWINSKA, Associate Professor, Head of the Molecular Pharmacology Group, School of Pharmaceutical Sciences, UNIGE
- Prof. Michel PRUDENT, Associate Professor, Head of Innovation and Therapeutic Products, Transfusion Interrégionale CRS SA; Centre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and UNIL
- Dr Grégory RESCH, Senior Lecturer, Head of the Bacteriophage and Phage Therapy Laboratory, Centre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and UNIL
Scientific committee
- Dr Grégory RESCH, Senior Lecturer, Head of the Bacteriophage and Phage Therapy Laboratory, Centre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and UNIL
- Dr Jean-François BRUNET, Head of the Cell Manufacturing Center, Service of Pharmacy, Lausanne University Hospital and UNIL
- Prof. Lana KANDALAFT, Chief of Service – Center of Experimental Therapeutics, Lausanne University Hospital and UNIL ; Associate Director for Clinical Translation – Ludwig Institute for Cancer Research
- Prof. Alexandre HARARI, Associate Professor, Head of the Tumor Immunology laboratory, Department of Oncology, Lausanne University Hospital and UNIL
- Dr Francesco CEPPI, Lecturer and Medical Oncologist, Unit of Pediatric Oncology Hematology, Lausanne University Hospital and UNIL
- Prof. Patrycja NOWAK-SLIWINSKA, Associate Professor, Head of the Molecular Pharmacology Group, School of Pharmaceutical Sciences, UNIGE
- Prof. Michel PRUDENT, Associate Professor, Head of Innovation and Therapeutic Products, Transfusion Interrégionale CRS SA; Centre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and UNIL
- Prof. Gerrit BORCHARD, Full Professor, Head of the Biopharmaceutics laboratory, School of Pharmaceutical Sciences, UNIGE
Contribution to the Sustainable Development Goals
